Takeuchi Satoshi, Honma Rio, Taguchi Jun, Amano Toraji, Shimizu Yasushi, Kinoshita Ichiro, Kubota Kanako, Matsuno Yoshihiro, Dosaka-Akita Hirotoshi
Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Case Rep Oncol. 2011 May;4(2):260-6. doi: 10.1159/000328802. Epub 2011 May 24.
High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with a huge liver tumor was diagnosed with high-grade neuroendocrine carcinoma originating from the liver. Multiple liver and bone metastases were found one month after surgery. He was treated with three chemotherapy regimens used for the management of small-cell lung cancer with extensive disease. However, none of them could be maintained because of tumor progression. He was then treated with bevacizumab plus modified FOLFOX6 as the fourth-line regimen. Dramatic tumor shrinkage was obtained, and a partial response was achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated with bevacizumab in combination with cytotoxic chemotherapy.
高级别神经内分泌癌与普通神经内分泌癌不同，其预后较差。在本病例报告中，介绍了一例以贝伐单抗联合改良FOLFOX6方案作为四线化疗后病情改善的高级别神经内分泌癌病例。一名29岁男性，患有巨大肝脏肿瘤，被诊断为起源于肝脏的高级别神经内分泌癌。术后1个月发现多发肝转移和骨转移。他接受了三种用于治疗广泛期小细胞肺癌的化疗方案。然而，由于肿瘤进展，这些方案均无法维持。随后他接受了贝伐单抗联合改良FOLFOX6方案作为四线治疗。肿瘤显著缩小，达到了部分缓解。该病例提示，高级别神经内分泌癌可采用贝伐单抗联合细胞毒性化疗进行治疗。
